Saracatinib
Src family kinase inhibitor / Potent and selective inhibitor of Src family kinases, IC50=4-10 nM for Src, c-Yes, Fyn, Lyn, Blk, Fgr and Lck.1 Demonstrates potent antimigratory, anti-invasive and antiproliferative activity and inhibits metastasis in a mouse model of bladder cancer.2 Inhibits MERS- CoV at early stages of the viral life cycle at mM concentrations.3,4 Rescues memory performance and reduces phospho-Tau accumulation in traumatic tauopathy.5 Rescues memory deficits and synaptic depletion in an Alzheimer’s mouse model.6
Biochemicals & reagents
379231-04-6
AZD0530
Hennequin et al. (2006), N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor; J. Med. Chem., 49 6465 Green et al. (2009), Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530; Oncol., 3 248 de Wispelaere et al. (2013), The small molecules AZD0530 and Dasatinib inhibit dengue virus RNA replication via Fyn kinase; Virol., 87 7367 Shin et al. (2018), Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro; Viruses, 10 283 Tang et al. (2020), Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic mice and traumatic Tauopathy; Acta Neuropathol. Commun., 8 96 Kaufman et al. (2015), Fyn inhibition rescues established memory and synapse loss in Alzheimer mice; Neurol., 77 953
-20°C
TARGET: Kinase -- PATHWAY: Cell migration; Proliferation; Cell adhesion; PI3k; ERK -- RESEARCH AREA: Neuroscience -- DISEASE AREA: Neurodegeneration; Infectious diseaseCancer